List of Excipients in Branded Drug EOHILIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TAKEDA PHARMACEUTICALS AMERICA INC	EOHILIA	budesonide	64764-105	ACESULFAME POTASSIUM
TAKEDA PHARMACEUTICALS AMERICA INC	EOHILIA	budesonide	64764-105	AMMONIUM GLYCYRRHIZATE
TAKEDA PHARMACEUTICALS AMERICA INC	EOHILIA	budesonide	64764-105	ANHYDROUS CITRIC ACID
TAKEDA PHARMACEUTICALS AMERICA INC	EOHILIA	budesonide	64764-105	ASCORBIC ACID

Last updated: August 27, 2026

EOHILIA is the first FDA-approved oral budesonide suspension specifically designed for eosinophilic esophagitis (EoE). Its commercial value depends on more than budesonide: the excipient system supports suspension uniformity, palatability, dose delivery, storage, and pediatric use. The main opportunity is to develop differentiated excipient systems, manufacturing platforms, and generic or 505(b)(2) alternatives that match EOHILIA’s clinical usability without copying protected formulation claims.

EOHILIA Excipient Strategy, Patent Protection, and Commercial Opportunities

What is EOHILIA and how does its formulation work?

EOHILIA is Takeda’s budesonide oral suspension for EoE. FDA approved the product in January 2024 for adults and pediatric patients aged 11 years and older who weigh at least 30 kg. The product is administered as a 2 mg/10 mL oral suspension for 12 weeks. FDA later expanded the labeling to younger pediatric patients, including children aged 1 year and older weighing at least 11 kg, with age- and weight-specific dosing reflected in the current prescribing information.[1,2]

EOHILIA is supplied as a ready-to-use, single-dose oral suspension. The formulation addresses several problems associated with conventional swallowed corticosteroid therapy:

• Budesonide has low aqueous solubility.
• Patients must deliver the drug to the esophageal mucosa rather than swallow it rapidly into the stomach.
• Pediatric patients often reject bitter or poorly textured products.
• Dose uniformity is difficult when the active ingredient is suspended rather than dissolved.
• The formulation must remain physically stable during storage and use.

The product’s commercial differentiation is therefore linked to delivery performance and administration convenience, not only to the active ingredient.

What excipients are used in EOHILIA?

The FDA prescribing information identifies the following inactive ingredients in EOHILIA:

Excipient	Likely formulation function
Xanthan gum	Suspending agent and viscosity modifier
Glycerin	Humectant, viscosity aid, and mouthfeel modifier
Polysorbate 80	Wetting and dispersion aid
Sucralose	Sweetener and taste-masking agent
Citric acid monohydrate	Acidulant and pH adjustment
Sodium citrate dihydrate	Buffering agent
Disodium edetate	Chelating agent and stability aid
Purified water	Continuous vehicle

The finished product is strawberry-flavored according to the product labeling.[1]

Why xanthan gum is commercially important

Xanthan gum is likely central to the product’s suspension architecture. It increases viscosity at low concentrations and can reduce sedimentation during storage. Its shear-thinning behavior also allows the product to flow during administration while maintaining suspension stability at rest.

For EOHILIA, xanthan gum must balance four competing requirements:

1. Sufficient viscosity to prevent rapid settling.
2. Easy pouring or oral administration.
3. Rapid redispersion without extensive shaking.
4. Acceptable mouthfeel for children and adolescents.

A generic developer that substitutes another polymer may achieve equivalent dose uniformity but create a different texture, sedimentation profile, or administration burden. Those differences can affect both regulatory comparability and commercial adoption.

Why polysorbate 80 matters

Polysorbate 80 can improve wetting of budesonide particles and support uniform dispersion in the aqueous vehicle. It can also reduce agglomeration and improve manufacturing reproducibility.

The excipient creates potential development constraints. Polysorbate 80 can undergo oxidative degradation, generate peroxides, and interact with packaging or active pharmaceutical ingredients. A developer seeking to remove or reduce polysorbate 80 would need to demonstrate equivalent particle wetting, suspension stability, assay uniformity, and impurity control.

Why the citrate buffer and disodium edetate are relevant

Citric acid and sodium citrate provide pH control. The pH affects budesonide stability, preservative strategy, flavor perception, polymer behavior, and compatibility with the container closure system.

Disodium edetate can bind trace metal ions that catalyze oxidation. Its presence indicates that chemical stability was likely considered alongside physical suspension stability. It may also help protect flavor components and the surfactant system during shelf life.

Why sucralose and glycerin support pediatric adherence

Sucralose masks bitterness, while glycerin contributes sweetness, viscosity, and mouthfeel. These excipients are commercially relevant because EoE treatment is often chronic even when a specific approved treatment course is limited to 12 weeks.

A formulation that produces less bitterness, less throat irritation, or a smoother texture could compete effectively even if it uses the same active ingredient and dose.

What formulation attributes create commercial value?

The most valuable attributes are those that improve treatment persistence and reduce administration failure.

Attribute	Commercial impact
Uniform budesonide concentration	Reduces underdosing and supports regulatory approval
Stable suspension	Limits settling and dose variability
Rapid redispersion	Improves use by children and caregivers
Palatable flavor	Supports adherence
Appropriate viscosity	Balances esophageal coating and swallowability
Single-dose packaging	Improves dose accuracy and portability
No refrigeration requirement	Simplifies pharmacy and household storage
Low container interaction	Reduces extractables, leachables, and potency risk
Robust microbial control	Supports shelf life and pediatric use

The delivery objective is not systemic absorption. The product is intended to deposit budesonide on the esophageal mucosa. A formulation that increases rapid swallowing may reduce local exposure even if pharmacokinetic measurements remain acceptable.

What patents protect EOHILIA?

EOHILIA’s principal intellectual-property risk is expected to arise from formulation and method-of-use protection rather than from the underlying budesonide molecule. Budesonide is an established corticosteroid with generic products and earlier approved formulations.

The relevant patent categories are:

Formulation patents

These may cover combinations of:

• Budesonide particle size or particle engineering.
• Suspending polymers.
• Surfactants and wetting agents.
• Buffer systems.
• Sweeteners and flavoring agents.
• Viscosity ranges.
• Redispersion characteristics.
• Single-dose oral suspension packaging.
• Stability profiles.

A claim directed broadly to “an oral suspension comprising budesonide and xanthan gum” would face greater validity and obviousness risk than a claim combining narrowly defined concentration ranges, particle properties, rheology, pH, and performance requirements.

Method-of-use patents

Method claims may address administration of budesonide oral suspension for EoE, including:

• Dose and dosing frequency.
• Treatment of adults and pediatric patients.
• Administration without food or drink for a specified period.
• Delayed eating or drinking after dosing.
• Use for histologic remission.
• Use for patients with dysphagia or food impaction risk.

Method-of-use claims can delay or complicate generic entry when they are listed in the FDA Orange Book and remain relevant to the approved indication. Their practical value depends on claim scope, enforceability, skinny-label options, and the extent to which the product’s commercial use is inseparable from the patented method.

Packaging and device-related rights

EOHILIA is supplied in unit-dose packaging. Intellectual property may cover the dose container, filling configuration, labeling, or administration system. Packaging claims are less likely to block all generic entry but may raise design-around costs and create supply-chain barriers.

Orange Book status

The FDA Orange Book is the controlling source for determining which patents Takeda has listed against EOHILIA, the patent expiration dates, and whether listed patents cover the drug product or an approved method of use.[3]

A commercial patent review should separate:

• Listed patents from unlisted applications.
• Orange Book expiration dates from patent-term-adjusted dates.
• Pediatric exclusivity from patent life.
• Formulation claims from method-of-use claims.
• United States rights from foreign patent families.

The existence of an Orange Book listing does not establish validity. It determines the statutory framework for ANDA certification and potential Paragraph IV litigation.

When does EOHILIA lose exclusivity?

EOHILIA’s regulatory exclusivity is distinct from its patent exclusivity.

Protection	Strategic significance
New drug approval exclusivity	Limits certain competing applications for the statutory period
Pediatric exclusivity	Can add six months to qualifying listed patents and exclusivities
Formulation patents	May delay an ANDA if valid and enforceable
Method-of-use patents	May support a full or partial indication barrier
Budesonide molecule	Does not provide meaningful new-molecule protection for EOHILIA

EOHILIA was approved through the FDA’s new drug application pathway, but the product contains an established active ingredient. The commercial protection therefore depends heavily on listed formulation and use patents, regulatory exclusivity, and the strength of Takeda’s clinical differentiation.[1,3]

The exact generic-entry date depends on the Orange Book patent listing, patent-term adjustments, pediatric extension, any Paragraph IV certifications, and litigation outcomes. A single “expiration date” is not sufficient for launch analysis.

Which companies could challenge EOHILIA?

The most likely challengers are established generic manufacturers with experience in:

• Budesonide oral products.
• Gastrointestinal suspensions.
• Pediatric liquid formulations.
• Complex ANDA submissions.
• Paragraph IV litigation.
• 505(b)(2) development.

Potential competitive pathways include:

ANDA pathway

An ANDA applicant could seek approval for a bioequivalent generic version and certify against EOHILIA’s listed patents. The central technical risks would include:

• Dose uniformity.
• Particle-size distribution.
• Suspension redispersion.
• Rheology.
• Container-closure performance.
• Comparative stability.
• Labeling restrictions for patented EoE use.

505(b)(2) pathway

A 505(b)(2) applicant could pursue a differentiated budesonide suspension, gel, mucoadhesive liquid, or other esophageal-delivery product. This pathway may be commercially attractive where the product differs in formulation, administration, dosage strength, or treatment duration.

A 505(b)(2) product could compete without being identical to EOHILIA. It might offer:

• Longer mucosal residence.
• Lower dosing frequency.
• Improved flavor.
• A preservative-free presentation.
• A different package or dispensing system.
• Use in additional age groups.
• A more convenient administration volume.

What generic-entry risks exist for EOHILIA?

The primary risks are technical, legal, and commercial.

Technical risk

Suspensions are more difficult to match than simple immediate-release tablets. A challenger must show that the drug product delivers consistent doses throughout the container or unit-dose package. Failure modes include sedimentation, caking, aggregation, poor wetting, and inconsistent redispersion.

Legal risk

A Paragraph IV challenge could trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions and court decisions.[4]

The most vulnerable claims would likely be narrow claims requiring specific excipient ratios, viscosity ranges, or particle properties. Broader claims could face prior-art and obviousness challenges, particularly because budesonide suspensions and common pharmaceutical excipients are well known.

Commercial risk

Even after patent clearance, a generic may face adoption barriers. Physicians and caregivers may value EOHILIA’s established flavor, unit-dose format, and instructions. A lower-priced product with inferior taste or more difficult redispersion may not rapidly displace the branded product.

How strong is the EOHILIA patent estate?

The patent estate is likely strongest where formulation claims are tied to measurable performance rather than a simple ingredient list.

Claim approach	Relative strength
Budesonide plus a conventional suspending agent	Vulnerable to prior-art challenges
Specific excipient combination	Moderate, depending on prior art
Defined particle size and polymer concentration	Stronger if technically supported
Narrow pH, viscosity, and stability ranges	Potentially strong but easier to design around
Esophageal treatment method	Commercially useful, enforcement-sensitive
Single-dose container configuration	Moderate; design-around may be available
Broad use of budesonide for EoE	Vulnerable if prior art or earlier clinical use exists

The strongest defensive position usually comes from layered rights: formulation patents, method-of-use patents, pediatric exclusivity, regulatory data, trademarks, clinical familiarity, and manufacturing know-how.

Trade secrets may be as important as published patents. These can include:

• Budesonide milling and dispersion procedures.
• Order of excipient addition.
• Hydration conditions for xanthan gum.
• Deaeration and filling parameters.
• Flavor-masking process controls.
• Hold-time limits.
• Container-closure specifications.
• In-process redispersion testing.

A competitor may design around a patent but still face a costly development program to reproduce the product’s physical and sensory performance.

What licensing opportunities exist around EOHILIA technology?

Licensing opportunities are more likely to involve platform technology than direct EOHILIA replication.

Excipient and formulation licensing

Companies with proprietary polymers, mucoadhesive systems, taste-masking technologies, or spray-dried budesonide particles could license their platforms to generic or specialty-pharma developers.

Regional commercialization rights

EOHILIA’s value may vary by geography because EoE diagnosis, reimbursement, and specialist access differ substantially. Regional partners could provide:

• Local regulatory execution.
• Pediatric clinical development.
• Gastroenterology promotion.
• Hospital and specialty-pharmacy access.
• Local manufacturing or packaging.

Follow-on product licensing

A partner could develop an improved budesonide product with:

• Once-daily dosing.
• Higher mucosal retention.
• Reduced administration volume.
• A more acceptable taste profile.
• Additional strengths.
• A broader pediatric indication.

The strongest licensing asset would combine a differentiated formulation with regulatory data and enforceable rights in major markets.

What manufacturing and intellectual-property barriers affect competitors?

EOHILIA manufacturing is more complex than conventional liquid filling because the product must maintain a reproducible suspension throughout processing and filling.

Key manufacturing barriers include:

• Uniform distribution of micronized budesonide.
• Controlled wetting of hydrophobic drug particles.
• Complete hydration of xanthan gum.
• Prevention of polymer clumping.
• Control of air incorporation and foam.
• Consistent unit-dose fill volume.
• Stability during shipping.
• Microbial and preservative strategy.
• Compatibility with plastic packaging.

A challenger must also qualify suppliers for pharmaceutical-grade xanthan gum, polysorbate 80, flavor components, and packaging materials. Excipient variability can change viscosity, sedimentation, and sensory performance from batch to batch.

How does EOHILIA compare with competing EoE treatments?

EOHILIA competes with swallowed topical corticosteroid strategies and dietary therapy.

Treatment approach	Delivery format	Main commercial limitation
EOHILIA	Budesonide oral suspension	Patent, price, and 12-week approved course
Swallowed budesonide nebulizer formulation	Off-label liquid administration	Variable preparation and dosing
Swallowed fluticasone inhaler	Off-label swallowed aerosol	Technique and dose-delivery variability
Proton-pump inhibitors	Oral tablets or capsules	Different mechanism and variable response
Elimination diets	Food restriction	Adherence and nutritional burden
Dupilumab	Injectable biologic	Cost, injection burden, and biosimilar timing

EOHILIA has no biosimilar risk because it is a small-molecule budesonide product. Its direct substitution risk comes from generics and 505(b)(2) products, not from the biosimilar pathway.

Dupilumab creates a separate competitive dynamic. It is a systemic biologic treatment for EoE and may be preferred for patients with more severe disease, multiple atopic conditions, or inadequate response to topical steroids. Its patent and biosimilar landscape is separate from EOHILIA’s.

What is the revenue exposure from EOHILIA patent loss?

Takeda does not generally report EOHILIA revenue as a standalone figure in the sources cited here. Revenue exposure should therefore be modeled through prescription volume, net price, payer coverage, and substitution timing rather than through a reported product-specific sales figure.

Key scenarios are:

Scenario	Commercial effect
No approved generic before patent expiry	Continued branded pricing and physician familiarity
First generic launch	Price erosion and pharmacy substitution
Multiple generic entrants	Rapid net-price compression
505(b)(2) differentiated entrant	Share loss without direct automatic substitution
Improved branded formulation	Lifecycle extension and defense against price erosion
Pediatric uptake expansion	Larger treated population and increased formulation value

The highest-value lifecycle strategy is likely a formulation improvement that can obtain separate patent protection and address adherence, dosing frequency, or pediatric acceptability.

Key Takeaways

• EOHILIA is a budesonide oral suspension designed for local esophageal delivery in EoE.
• Its excipient system includes xanthan gum, glycerin, polysorbate 80, sucralose, citrate buffer components, disodium edetate, and water.
• Suspension stability, redispersion, viscosity, flavor, and dose uniformity are the core commercial differentiators.
• Budesonide’s old active-ingredient status means EOHILIA relies on formulation patents, method-of-use patents, regulatory exclusivity, and know-how.
• Generic challengers face complex suspension-development requirements, but an ANDA pathway remains available subject to Orange Book patents and certifications.
• A 505(b)(2) product could compete through improved mucosal retention, taste, dosing frequency, or pediatric usability.
• EOHILIA has generic and 505(b)(2) risk, but no biosimilar risk.
• The most attractive licensing opportunities involve excipient platforms, mucoadhesive delivery, taste masking, regional commercialization, and lifecycle reformulation.
• The FDA Orange Book remains the authoritative source for current listed patents, certifications, and expiration analysis.

FAQs About EOHILIA Excipient and Commercial Strategy

Does EOHILIA contain a preservative?

The FDA labeling identifies disodium edetate and other formulation excipients but does not characterize EOHILIA as a conventional preservative-containing multidose suspension. The product’s single-dose presentation reduces the microbial-control burden associated with repeated container opening.[1]

Can a generic replace EOHILIA automatically at the pharmacy?

Automatic substitution depends on FDA therapeutic-equivalence ratings, state substitution law, and the final approved generic label. A 505(b)(2) product would not necessarily receive the same substitution treatment as an AB-rated ANDA product.

Is xanthan gum essential to EOHILIA?

Xanthan gum is a major suspending and rheology-control excipient in the labeled formulation. A competing product could use another polymer, but it would need to demonstrate comparable physical stability, dose uniformity, usability, and clinical performance.

Could a budesonide gel compete with EOHILIA?

Yes. A budesonide gel or mucoadhesive formulation could pursue a 505(b)(2) strategy if it provides a differentiated delivery profile, administration method, or clinical benefit. It would face its own formulation, clinical, and patent requirements.

Does EOHILIA have protection outside the United States?

Patent and regulatory protection must be assessed separately in each jurisdiction. United States Orange Book listings do not establish protection in Europe, Canada, Japan, or other markets.

References

1. U.S. Food and Drug Administration. (2024). EOHILIA (budesonide) oral suspension prescribing information. Takeda Pharmaceuticals U.S.A., Inc.

2. U.S. Food and Drug Administration. (2024). FDA approves first oral treatment for eosinophilic esophagitis. https://www.fda.gov

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2023). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/fda-drug-approval-process-generic-drugs/abbreviated-new-drug-application-anda-forms-and-guidance-available-anda-applicants